Why have we failed to achieve neuroprotection in Parkinson's disease?
- 6 January 2009
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 64 (S2), S101-S110
- https://doi.org/10.1002/ana.21461
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson diseaseNeurology, 2007
- The pathogenesis of cell death in Parkinson's disease – 2007Movement Disorders, 2007
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialThe Lancet Neurology, 2006
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest studyMovement Disorders, 2006
- Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson diseaseAnnals of Neurology, 2006
- Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 yearsMovement Disorders, 2004
- Molecular Pathways of Neurodegeneration in Parkinson's DiseaseScience, 2003
- An algorithm (decision tree) for the management of Parkinson’s disease (2001):Neurology, 2001
- l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In VitroJournal of Neurochemistry, 1997
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993